DOCK 8 Inhibitors
DOCK8 inhibitors are a class of chemical compounds that specifically target and inhibit the activity of the Dedicator of Cytokinesis 8 (DOCK8) protein, which is a member of the DOCK family of guanine nucleotide exchange factors (GEFs). DOCK8 is a crucial regulator of the actin cytoskeleton and plays a significant role in various cellular processes, including cell migration, immune cell function, and the maintenance of cellular morphology. By inhibiting DOCK8, these compounds disrupt the signaling pathways that are essential for actin reorganization, providing researchers with tools to study the molecular mechanisms underlying cell movement and structural integrity. The inhibition of DOCK8 is particularly valuable in investigating how cells, especially immune cells, navigate through tissues and respond to environmental cues, which is critical for understanding immune responses and cell trafficking.
In research settings, DOCK8 inhibitors are employed to dissect the role of DOCK8 in cellular signaling networks. These inhibitors allow scientists to pinpoint the specific contributions of DOCK8 to actin dynamics and to explore how its inhibition affects the broader cellular architecture and function. By using DOCK8 inhibitors, researchers can investigate the downstream effects of disrupted DOCK8 activity, such as changes in cell shape, impaired migration, and altered interactions with other cells. Additionally, these inhibitors are instrumental in studying the cross-talk between DOCK8 and other signaling molecules, helping to elucidate the complex regulatory networks that govern cellular behavior. Through the use of DOCK8 inhibitors, scientists gain deeper insights into the molecular underpinnings of cell movement and the critical role that DOCK8 plays in orchestrating these processes, thereby advancing the understanding of cellular dynamics in various biological contexts.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
FTY720 | 162359-56-0 | sc-202161 sc-202161A sc-202161B | 1 mg 5 mg 25 mg | $32.00 $75.00 $118.00 | 14 | |
Fingolimod is an S1P receptor modulator that affects the sphingosine-1-phosphate (S1P) signaling pathway. It inhibits the migration and activation of lymphocytes, which indirectly reduces the activation of DOCK 8 since DOCK 8 is involved in T-cell signaling and migration processes influenced by the S1P pathway. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is a phosphoinositide 3-kinase (PI3K) inhibitor that targets the PI3K/AKT signaling pathway. It indirectly inhibits DOCK 8, as DOCK 8 is known to interact with PI3K. Inhibition of PI3K disrupts downstream signaling, affecting DOCK 8 activity in processes like cytoskeletal rearrangement and cell motility. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $47.00 $145.00 | 51 | |
Dasatinib is a kinase inhibitor that targets multiple tyrosine kinases, including SRC family kinases. DOCK 8 interacts with kinases in various signaling cascades. By inhibiting SRC kinases, Dasatinib indirectly interferes with DOCK 8-mediated pathways involved in cell adhesion, migration, and signaling. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin is an mTOR inhibitor that regulates the mTOR pathway. DOCK 8 plays a role in the regulation of T-cell migration and immune cell activation. By inhibiting mTOR, Rapamycin indirectly influences DOCK 8 activity, affecting T-cell functions and immune responses mediated by DOCK 8. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 is a p38 MAPK inhibitor that targets the p38 MAPK signaling pathway. DOCK 8 is involved in immune cell signaling and cytoskeletal organization influenced by p38 MAPK. Inhibition of p38 MAPK by SB203580 indirectly modulates DOCK 8, impacting immune cell functions and migration processes. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a PI3K inhibitor that blocks the PI3K/AKT pathway. DOCK 8 interacts with PI3K in cellular processes. Inhibition of PI3K by LY294002 indirectly affects DOCK 8 activity, influencing processes like immune cell migration and cytoskeletal rearrangement. | ||||||
Selumetinib | 606143-52-6 | sc-364613 sc-364613A sc-364613B sc-364613C sc-364613D | 5 mg 10 mg 100 mg 500 mg 1 g | $28.00 $80.00 $412.00 $1860.00 $2962.00 | 5 | |
Selumetinib is a MEK1/2 inhibitor that targets the MAPK/ERK pathway. DOCK 8 is associated with this pathway's regulation. By inhibiting MEK1/2, Selumetinib indirectly modulates DOCK 8, impacting cellular functions like T-cell activation and immune cell migration. | ||||||
Ruxolitinib | 941678-49-5 | sc-364729 sc-364729A sc-364729A-CW | 5 mg 25 mg 25 mg | $246.00 $490.00 $536.00 | 16 | |
Ruxolitinib is a JAK1/2 inhibitor that affects the JAK/STAT signaling pathway. DOCK 8 is involved in immune cell signaling influenced by JAK/STAT. Inhibition of JAK1/2 by Ruxolitinib indirectly influences DOCK 8 activity, affecting immune responses and lymphocyte activation. | ||||||
SB 431542 | 301836-41-9 | sc-204265 sc-204265A sc-204265B | 1 mg 10 mg 25 mg | $80.00 $212.00 $408.00 | 48 | |
SB431542 is a TGF-β receptor inhibitor that targets the TGF-β signaling pathway. DOCK 8 interacts with molecules affected by TGF-β signaling. Inhibition of TGF-β receptor by SB431542 indirectly modulates DOCK 8, influencing processes like T-cell differentiation and migration. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is a JNK inhibitor that specifically blocks the JNK signaling pathway. DOCK 8 plays a role in immune cell signaling influenced by JNK. Inhibition of JNK by SP600125 indirectly interferes with DOCK 8 activity, impacting processes such as T-cell activation and migration. | ||||||